Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.
Type:
Grant
Filed:
December 7, 2006
Date of Patent:
January 8, 2013
Assignee:
Clavis Pharma AS
Inventors:
Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
Abstract: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.
Type:
Application
Filed:
November 15, 2010
Publication date:
November 17, 2011
Applicant:
CLAVIS PHARMA AS
Inventors:
Sayeh Ahrabi, Finn Myhren, Ole Henrik Eriksen
Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula (I)” herein. Compounds of formula (I) can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
Type:
Application
Filed:
December 7, 2006
Publication date:
March 11, 2010
Applicant:
CLAVIS PHARMA AS
Inventors:
Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
Abstract: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.
Type:
Application
Filed:
March 7, 2006
Publication date:
November 13, 2008
Applicant:
Clavis Pharma AS
Inventors:
Finn Myhren, Marit Liland Sandvold, Ole Henrick Eriksen
Abstract: The present invention relates to oral dosage forms of certain long chain saturated and monounsaturated fatty acid derivatives of 2?,2?-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to the use of the said gemcitabine derivatives or a pharmaceutical acceptable salt thereof for preparing an oral dosage form ameliorating compliance in treatment of cancer.
Type:
Application
Filed:
March 21, 2006
Publication date:
September 27, 2007
Applicant:
Clavis Pharma AS
Inventors:
Finn Myhren, Marit Sandvold, Ole Eriksen
Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives are referred to as “Compounds of formula I” herein. Compounds of formula I can be used in the treatment of a cancerous disease. Treatment of both solid tumours and haematological cancers such as leukaemias, lymphomas and multiple myelomas are included.
Type:
Application
Filed:
December 19, 2005
Publication date:
June 14, 2007
Applicant:
Clavis Pharma AS
Inventors:
Finn Myhren, Marit Sandvold, Steinar Hagen, Ole Eriksen
© 2026 Justia
